SAGE News and Press, Sage Therapeutics Inc. From 11/06/23

2023-11-06 15:12:41 ET More on Sage Therapeutics Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024 Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage granted FDA orphan tag for Huntington’s disease therapy ...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November 7, 2023 at 8:00 a.m. ET to review third quarter 2023 financial results and discuss recent business ...

2023-10-18 18:52:03 ET Summary Sage Therapeutics, Inc. received FDA approval along with Biogen for its drug ZURZUVAE for the treatment of postpartum depression, with a planned launch in Q4 2023. The company has several ongoing studies using its drug SAGE-718 for the treatment of H...

2023-10-18 11:28:36 ET More on Sage Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage Therapeutics, Inc. (SAGE) Business Update Call (Transcript) Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market Sage cuts 40% of staff...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington’s disease (HD). SAGE...

2023-09-08 17:10:24 ET Gainers: Vigil Neuroscience ( NASDAQ: VIGL ) +7% . Tenaya Therapeutics ( TNYA ) +4% . CorMedix ( CRMD ) +4% . Xeris Biopharma  ( XERS ) +3% . Avidity Biosciences ( RNA ) +3% . Losers: The L...

2023-09-06 14:27:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regard...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the following upcoming investor conferences in September: Morgan Stanley 21 st Annual Global Healthcare Conf...

2023-09-05 08:27:58 ET Summary Biogen receives FDA approval for Leqembi, a treatment for Alzheimer's Disease, providing a large market opportunity. Biogen's acquisition of Reata Pharmaceuticals brings the potential for significant sales growth with SKYCLARYS, a drug for Friedreich...

2023-08-31 07:22:43 ET More on Sage Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage Therapeutics, Inc. ( SAGE ) Business Update Call (Transcript) Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market Sage Therapeutic...